Belluscura (LSE:BELL) Other Current Receivables: £0.00 Mil (As of Jun. 2024)


What is Belluscura Other Current Receivables?

Belluscura LSE:BELL Other Current Receivables is £0.00 Mil as of Jun. 2024.

Belluscura's Other Current Receivables for the quarter that ended in Jun. 2024 was £0.00 Mil.

Belluscura's annual Other Current Receivables increased from Dec. 2021 (£1.74 Mil) to Dec. 2022 (£2.21 Mil) but then declined from Dec. 2022 (£2.21 Mil) to Dec. 2023 (£0.96 Mil).

Belluscura Other Current Receivables Related Terms

Belluscura Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Belluscura's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Belluscura Other Current Receivables Chart

Belluscura Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Receivables
Get a 7-Day Free Trial 0.01 0.14 1.74 2.21 0.96

Belluscura Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 2.21 0.00 0.96 0.00

Belluscura Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of £0.00 Mil mean?
Belluscura (LSE:BELL) has a Other Current Receivables of £0.00 Mil as of Jun. 2024. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Belluscura and its competitors.
Is Belluscura's Other Current Receivables too high?
Belluscura's current Other Current Receivables is £0.00 Mil.
How does Belluscura's Other Current Receivables compare to ABT and BSX?
Belluscura's Other Current Receivables of £0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Medical Devices & Instruments company?
A good Other Current Receivables depends on the Medical Devices & Instruments industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Belluscura and its competitors. Belluscura's current Other Current Receivables is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Belluscura stock overvalued right now?
Belluscura (LSE:BELL) has a current Other Current Receivables of £0.00 Mil. The current Other Current Receivables is £0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Belluscura (LSE:BELL), the current Other Current Receivables is £0.00 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Belluscura Business Description

Address 15 Fetter Lane, Holborn, London, GBR, EC4A 1BW
Belluscura PLC is a medical device company. Its first product, the X-PLOR, is a lightweight FDA-cleared portable oxygen concentrator designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The company has only one operating segment being the sale of oxygen concentrators in the United States. The X-PLO2R weighs less than 1.5kg (3.25 lbs) and it is the first modular portable oxygen concentrator it will generate more oxygen by weight than any other FDA-cleared POC in its class. It either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments.